A rare manifestation – Bleomycin-induced skin toxicity

Bleomycin-induced skin toxicity is a rare but significant adverse reaction. This case report discusses a 25-year-old male undergoing chemotherapy for classical Hodgkin’s lymphoma (nodular sclerosis) who developed flagellate cutaneous hyperpigmentation and erythematous plaques during his 5 th cycle of adriamycin, bleomycin, vincristine and dacarbazine chemotherapy. The World Health Organisation-Uppsala Monitoring Centre causality assessment classified this reaction as probable/likely. Dermatologic manifestations of bleomycin toxicity range from minor hyperpigmentation to severe desquamation, often requiring drug discontinuation. This report highlights the importance of early identification and intervention in bleomycin-induced skin toxicity.